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DITORIAL
itamin  D deﬁciency  (VDD):  the culprit  of cardiometabolic
iseases?,
eﬁciência  de  vitamina  D  (DVD):  o  responsável  por  doenc¸as
ardiometabólicas?
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t’s  commonly  believed  that  vitamin  D  only  plays  a  role  in
one health  maintenance  and  calcium  phosphate  homeo-
tasis regulation.  This  limited  recognition  of  vitamin  D’s
unction can  be  traced  back  to  its  discovery  through  the
ght against  rickets  almost  a  century  ago.  Further  studies
evealed several  other  roles  vitamin  D  plays  in  the  human
ody; its  importance  in  bone  related  health  is  merely  the
ip of  the  iceberg.
Until now,  studies  have  highlighted  that  the  receptor  for
itamin D  is  quite  ubiquitous,  residing  in  almost  all  the  major
uman organs,  including  the  heart,  brain,  livers,  kidneys,
ones, urinary  system,  and  parathyroid  glands.1,2 It’s  worth
oting that  vitamin  D  receptors  are  expressed  in  some  seem-
ngly unrelated  tissues,  for  example,  all  kinds  of  immune
ells, pancreatic    cells,  neurons,  as  well  as  vascular  smooth
ells, epithelial  cells,  and  cardiomyocytes  in  the  cardiovas-
ular system.  Through  those  widely  distributed  receptors,
itamin D  regulates  the  expression  of  over  200  genes  directly
r indirectly.3 It  partially  explains  why  vitamin  D  deﬁciency
as been  reported  to  be  associated  with  different  kinds
f diseases,  such  as  hypertension,  multiple  sclerosis,  colon
ancer, and  diabetes.  Due  to  the  gene  polymorphism  of  vita-
in  D  receptors,  there  is  individual  variation  in  vitamin
 reaction.  Recent  progress  in  the  study  of  the  vitamin  D
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eceptor  regulating  mechanism  has  greatly  advanced  the
nderstanding of  diseases  related  to  this  vitamin.
Among  all  research  on  the  role  of  vitamin  D  beyond  the
one system,  the  correlation  between  vitamin  D  deﬁciency
VDD) and  cardiometabolic  diseases  has  been  a  hotspot.
s there  any  causative  relationship  between  VDD  and  car-
iometabolic diseases?  If  so,  which  is  the  cause  and  which
s the  consequence?  Although  there  is  not  yet  a  deﬁnitive
nswer, accumulating  evidence  clearly  points  to  the  close
orrelation between  the  two.
Research  from  different  ﬁelds  and  perspectives  pro-
ides evidence  supporting  the  conclusion  that  VDD  and
ardiometabolic diseases  are  closely  related.  Firstly,  com-
ined results  from  the  NHANES  Ш  cross-sectional  study,  the
PFS cohort  study,  and  the  NHS  I  research  revealed  a  reverse
orrelation between  serum  25(OH)  D  levels  and  blood
ressure.4,5 Another  detailed  randomized  control  study  fur-
her conﬁrmed  that  vitamin  D  lowered  the  systolic  pressure,
hile leaving  the  diastolic  pressure  unaffected.6,7 Secondly,
he current  knowledge  of  VDD  and  diabetes  mellitus  type
 (DMT2)  is  largely  derived  from  epidemic  studies.  A  cross-
ectional study  indicated  that  serum  25(OH)D  levels  in  DMT2
ere dramatically  reduced.8 A  cohort  study  demonstrated
hat low  levels  of  25(OH)D  could  be  used  as  a  biomarker
o predict  the  development  and  progress  of  DMT2.9 It  is
elieved that  vitamin  D  supplementation  could  regulate
nsulin sensitivity,  and  thus  ameliorate  insulin  resistance  and
ven beneﬁt  pancreatic    cell  secretion.10 It  has  also  been
emonstrated that  adult  VDD  baseline  levels  are  reversely
orrelated with  ten-year  risk  of  metabolic  syndrome,  and
ndependent of  factors  such  as  gender,  age,  weight,  season
f the  year,  and  smoking.9 A  cross-sectional  study  con-
rmed that  VDD  was  linked  to  the  development  of  metabolic
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1. Heaney RP, Horst RL, Cullen DM, Armas LA. Vitamin D3 distribu-Vitamin  D  deﬁciency  (VDD):  the  culprit  of  cardiometabolic  d
syndrome  in  adults,  young  adults,  and  adolescents,11 and
that VDD  was  reversely  correlated  with  ﬁve-year  waistline,
triglycerides (TG),  fasting  blood  glucose  levels,  and  insulin
resistance. Additionally,  a  recent  cohort  study  conﬁrmed
that proper  25(OH)D  levels  could  largely  reduce  all-cause
and cardiovascular  mortality  in  patients  with  metabolic
syndrome.12 Lastly,  cross-sectional  and  prospective  cohort
studies have  observed  a  higher  incidence  of  cardiovascular
disease in  the  VDD  population,13 and  VDD  greatly  increased
the risk  of  cardiac  death  caused  by  heart  failure  and  sudden
cardiac arrest  in  White  coronary  angiography  candidates.14
The  abovementioned  studies  barely  addressed  chil-
dren and  adolescents,  and  Kelishadi  et  al.15 explored  the
relationship among  VDD,  insulin  resistance,  and  related
cardiometabolic disease  risk  factors  such  as  blood  glu-
cose, blood  pressure,  blood  lipids,  and  obesity  in  obese
children with  vitamin  D  supplementation.  The  authors  con-
cluded that  vitamin  D  supplementation  was  beneﬁcial  to
cardiometabolic disease  control  in  obese  children  and  ado-
lescents. This  is  the  evidence  regarding  the  correlation
between VDD  and  cardiometabolic  diseases  in  younger  popu-
lations.
However, there  are  some  caveats  in  the  research  by
Kelishadi et  al.15 Firstly,  a  control  group  of  normal-weight
children is  necessary,  since  there  was  no  data  demonstrat-
ing that  vitamin  D  levels  in  the  obese  children  was  lower
than that  of  eutrophic  children;  this  was  assumed  by  the
authors based  on  a  previous  result.16 If  there  were  no  obvi-
ous differences  of  vitamin  D  levels  between  the  subjects
of the  study  and  the  eutrophic  population,  the  rationale  of
vitamin D  interference  would  be  a  concern.
Secondly,  to  meet  the  statistical  analysis  requirement,
the authors  carefully  designed  the  experiment  to  guaran-
tee that  there  were  at  least  20  samples  in  each  group,
and that  there  was  positive  result  in  each  group.  However,
the authors  didn’t  describe  in  detail  the  standards  applied
to decide  which  samples  would  be  included,  especially
regarding the  differentiation  between  simple  obesity  from
secondary obesity  that  should  be  excluded.  It’s  unknown
whether vitamin  D  supplementation  would  be  effective  in
secondary obesity  patients,  in  whom  VDD  is  probable.  It  was
unclear why  the  authors  chose  obese  children  and  adoles-
cents aged  10  to  16  years  old,  and  it  is  quite  possible  that  the
data accuracy  and  conclusion  validity  might  have  be  compro-
mised due  to  the  inconsistency  of  the  baseline  for  different
populations included  in  the  study.  To  deﬁne  cardiometabolic
risk factors  and  metabolic  syndrome,  the  authors  applied
the latest  cut-off  points  provided  by  the  National  Heart,
Lung, and  Blood  Institute  for  the  pediatric  age  group  and  the
continuous value  of  metabolic  syndrome  (cMetS)  score,  as
recommended by  the  American  Diabetes  Association  and  by
the European  Association  for  the  Study  of  Diabetes  for  chil-
dren and  adolescents,  respectively.  It  is  a  concern  whether
these standards  are  appropriate  for  the  study  and
whether they  reﬂect  the  true  situation  of  the  popula-
tion of  interest.  Analyzing  previous  research  on  VDD  and
cardiometabolic diseases,  it’s  natural  to  hypothesize  that
a small  sample  pool  and  improper  sample  selection  are
important reasons  for  the  negative  results  obtained  by  the
authors.17,18 Therefore,  if  the  authors  had  expanded  their
sample size  and  applied  more  stringent  sample  selection
standards, they  could  have  possibly  observed  the  impactses?  5
f  vitamin  D  to  fasting  blood  glucose  level  and  blood  pres-
ure, rendering  their  result  more  convincing  and  valuable  to
linical and  practical  applications.
Moreover,  the  authors  should  have  considered  drug
elivery and  efﬁcacy.  Vitamin  D  capsules  were  orally  admin-
strated in  the  study,  and  it  is  common  sense  that  oral
elivery is  subject  to  potential  absorption  difﬁculty,  thus
ffecting the  vitamin  D  level  of  the  study  subjects  and  inter-
ering with  the  results  and  conclusions.  Furthermore,  the
uthors should  have  taken  into  account  the  vitamin  D  sup-
lement dosage,  the  frequency  of  administration,  and  the
otential adverse  effects  of  vitamin  D.
Additionally,  the  length  of  vitamin  D  supplementation
reatment and  validity  of  the  statistical  analysis  are  poten-
ial factors  that  affect  the  study  result.  For  example,  it
ould have  been  constructive  to  compare  within  male  and
emale sub-groups.
In short,  due  to  all  the  caveats  of  the  experiment  design
nd analysis  described  above,  although  Kelishadi  et  al.15
btained  positive  data  supporting  their  hypothesis  that  VDD
s  correlated  with  cardiometabolic  diseases  in  younger  popu-
ations, caution  should  be  exerted  when  interpreting  their
esults into  practical  applications.  It  would  be  better  to  ﬁrst
onﬁrm their  result  with  larger  samples  pools  and  more  care-
ul study  designs  if  necessary.  For  instance,  Kelishadi  et  al.15
entioned  that  there  are  several  reports  on  the  irrelevance
f VDD  and  cardiometabolic  diseases  in  different  age  popula-
ions. A  similar  result  was  reported  by  the  author  in  another
rticle.19 By  summarizing  the  available  animal  model  or
uman research  on  this  issue,  regardless  of  the  method  used
simple observation  or  systematic  random  control  study),  a
reat discrepancy  was  observed  regarding  the  ﬁnal  conclu-
ion, i.e.,  it  is  still  poorly  understood  whether  there  is
ausative relationship  between  VDD  and  cardiometabolic
iseases. Better--designed,  large  randomized  control  trials
f higher  quality  are  necessary  to  further  address  the  true
ole of  VDD  in  cardiometabolic  diseases.
To  summarize,  although  there  are  limitations  to  the  study
y Kelishadi  et  al.,15 their  results  are  still  valuable  to  the
eld and  advance  the  VDD  research  by  expanding  the  anal-
sis to  the  younger  obese  population,  which  is  more  prone
o cardiovascular  diseases.  It  is  a  pioneering  exploration  on
he beneﬁts  of  vitamin  D  supplementation  to  insulin  resis-
ance and  obesity-related  cardiovascular  risk  factors  in  a
on-adult population.  Not  only  does  it  meet  the  current
eed to  strengthen  the  study  and  prevention  of  chronic
on-infectious diseases  worldwide,  it  also  opens  a  window
o help  pave  the  road  for  further  study  on  VDD  and  car-
iometabolic diseases.
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